Rezenopy Spray
Product Images NDC 83245-003

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Rezenopy (NDC 83245-003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Scienture Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chem Structure (Rezenopy Naloxone HCl Nasal Spray 1)

Chemical structure of naloxone hydrochloride dihydrate, showing the molecular formula C19H21NO4·HCl·2H2O and a relative molecular mass of 399.87. The diagram includes the arrangement of rings and functional groups characteristic of naloxone.*

FDA Label Image

Figure G (Rezenopy Naloxone HCl Nasal Spray 10)

An instructional illustration labeled Figure G depicting a person tilting their head backward with one hand placed on their forehead and the other hand under their chin, demonstrating a method for opening the airway, often used in conjunction with nasal spray administration.*

FDA Label Image

Figure H (Rezenopy Naloxone HCl Nasal Spray 11)

An instructional illustration showing a hand administering a nasal spray to a person's nostril. An arrow indicates pressing the spray device into the nostril, demonstrating the correct usage technique for nasal drug delivery.*

FDA Label Image

Figure I (Rezenopy Naloxone HCl Nasal Spray 12)

An illustration showing a smartphone screen with the numbers '911' displayed prominently above a telephone handset icon, typically representing an emergency call screen. Labeled as 'Figure I'.*

FDA Label Image

Figure J (Rezenopy Naloxone HCl Nasal Spray 13)

An instructional diagram showing the recovery position for a person. It depicts a person lying on their side with one hand supporting the head and the opposite knee preventing the body from rolling over. A clock icon indicates a 2 to 3 minute waiting period, with an instruction to put in recovery position and watch. The figure is labeled as Figure J.*

FDA Label Image

Figure K (Rezenopy Naloxone HCl Nasal Spray 14)

An instructional illustration showing a hand holding a nasal spray device aimed at a person's nostril with the text prompt "Use Other Nostril." The image likely demonstrates how to correctly administer the nasal spray by using the opposite nostril.*

FDA Label Image

Figure L (Rezenopy Naloxone HCl Nasal Spray 15)

An instructional illustration labeled as Figure L shows a person lying on their side with an arrow pointing toward their back, indicating proper positioning, likely related to the use or administration of a nasal spray product.*

FDA Label Image

Figure M (Rezenopy Naloxone HCl Nasal Spray 16)

Illustration showing a hand discarding a nasal spray applicator into a trash bin labeled "Trash." This likely represents proper disposal instructions for the REZENOPY nasal spray device.*

FDA Label Image

Carton (Rezenopy Naloxone HCl Nasal Spray 17)

The REZENOPY nasal spray packaging label displays naloxone HCl 10 mg spray for nasal use. The label shows storage information, usage instructions, and warnings. It contains 2 nasal spray devices, each with one dose, manufactured by Scienture LLC. The label advises use in the nose only, not to remove from the blister or test before use, and includes emergency and disposal instructions.*

FDA Label Image

Figure 1 (Rezenopy Naloxone HCl Nasal Spray 2)

A line graph comparing naloxone plasma concentrations (ng/mL) over time (minutes) for three forms: REZENOPY nasal spray 10 mg, 0.4 mg intramuscular injection, and 2 mg intravenous injection. The REZENOPY spray shows increasing plasma levels over time, distinct from the other two injection forms.*

FDA Label Image

Figure 2 (Rezenopy Naloxone HCl Nasal Spray 3)

A line graph comparing naloxone plasma concentrations over time in hours following administration of REZENOPY nasal spray 10 mg, 0.4 mg intramuscular injection, and 2 mg intravenous injection. The y-axis shows naloxone plasma concentrations in ng/mL, with values declining over an 8-hour period.*

FDA Label Image

Figure A (Rezenopy Naloxone HCl Nasal Spray 4)

An instructional illustration showing the labeled components of a nasal spray device, specifically the nozzle and plunger, used for administering nasal spray medication. The diagram identifies these parts to aid in understanding the device's operation.*

FDA Label Image

Figure B (Rezenopy Naloxone HCl Nasal Spray 5)

An instructional illustration labeled as Figure B showing a person lying on their side with one arm extended above their head and the other arm bent, supporting the head. This posture is typically used for positioning someone in the recovery position.*

FDA Label Image

Figure C (Rezenopy Naloxone HCl Nasal Spray 6)

Illustration labeled Figure C shows a person lying flat on their back with their head tilted backward. An arrow indicates the motion of tilting the head to open the airway, commonly used to demonstrate positioning for nasal spray administration or airway management.*

FDA Label Image

Figure D (Rezenopy Naloxone HCl Nasal Spray 7)

An illustration showing hands opening a package and lifting out an item, likely an instructional graphic for accessing the product. The image is labeled as Figure D and demonstrates the removal of a nasal spray device from its clear plastic packaging.*

FDA Label Image

Figure E (Rezenopy Naloxone HCl Nasal Spray 8)

An instructional illustration showing a hand holding a nasal spray device, with the index and middle fingers positioned on top and the thumb underneath, demonstrating how to properly grip the device for administration. The image is labeled Figure E.*

FDA Label Image

Figure F (Rezenopy Naloxone HCl Nasal Spray 9)

Instructional illustration showing a person lying on their back with one hand supporting the neck and head, tilted backward to open the airway. This diagram, labeled 'Figure F,' is likely part of usage instructions for the nasal spray product REZENOPY (naloxone HCl 10 mg/.11mL).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.